Emerging Novel Biomarkers in Acute Coronary Syndrome Management: Insights and Future Directions

Abstract

Acute coronary syndrome (ACS), a primary manifestation of coronary artery disease (CAD), remains a leading cause of global mortality, particularly in low-and middle-income countries. Despite advances in diagnostics and therapy, accurate early risk stratification of ACS remains challenging. Traditional biomarkers such as cardiac troponins and CK-MB are essential for diagnosis but do not capture the full complexity of disease severity, particularly in cases involving inflammation, endothelial dysfunction and plaque instability. This review highlights emerging evidence regarding the roles of inflammatory cytokines and novel biomarkers in ACS pathophysiology, diagnosis and prognostication. Pro-inflammatory cytokines such as IL-6, IL-18 and TNF-α play key roles in atherogenesis and plaque destabilization, whereas anti-inflammatory mediators such as IL-10 and TGF-β decrease vascular injury. Novel biomarkers including Copeptin, GDF-15, microRNAs, sST2, Galectin-3, Endocan and MMP-9 offer enhanced prognostic capabilities and, in contrast to traditional biomarkers, often provide additional prognostic information in specific scenarios. Integrating these biomarkers with advanced risk models such as the GRACE score and digital health technologies, including AI, is transforming ACS management. However, challenges persist in standardization, cost-effectiveness, real-time implementation and interpretation in comorbid populations. This review emphasizes the potential of these biomarkers in improving personalized care and treatment for patients with ACS, while addressing evidence levels, clinical bottlenecks and integration strategies.

Keywords

Biomarkers / Acute Coronary Syndrome / Inflammatory markers / Cytokines

References

[1] De Alwis M, Wijesinghe N.Coronary artery disease. J Cey Coll Phys. 2023. Vol. 54(2):153-8

[2] Stark B, Johnson C, Roth GA. Global prevalence of coronary artery disease: an update from the global burden of disease study. J Am Coll Cardiol. 2024. Vol. 83 Suppl 13:2320

[3] de Oliveira Laterza Ribeiro M, Correia VM, Herling de Oliveira LL, Soares PR, Scudeler TL. Evolving diagnostic and management advances in coronary heart disease. Life (Basel). 2023. Vol. 13(4):951

[4] Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022. Vol. 80(25):2361-71

[5] Wang H, Liu Z, Shao J, Lin L, Jiang M, Wang L, et al.. Immune and inflammation in acute coronary syndrome: molecular mechanisms and therapeutic implications. J Immunol Res. 2020. Vol. 2020(1):4904217

[6] Angiolillo DJ, Biasucci LM, Liuzzo G, Crea F. [ Inflammation in acute coronary syndromes: mechanisms and clinical implications]. Rev Esp Cardiol. 2004. Vol. 57(5):433-46.

[7] Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006. Vol. 86(2):515-81

[8] Mallat Z, Corbaz A, Scoazec A, Besnard S, Lesèche G, Chvatchko Y, et al.. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001. Vol. 104(14):1598-603

[9] Junghans C, Timmis AD. Risk assessment after acute coronary syndrome. Br Med J. 2006. Vol. 333(7578):1079-80

[10] Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the HEART score. Neth Heart J. 2008. Vol. 16(6):191-6

[11] Libby P.Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012. Vol. 32(9):2045-51

[12] Kraler S, Mueller C, Libby P, Bhatt DL. Acute coronary syndromes: mechanisms, challenges, and new opportunities. Eur Heart J. 2025. Vol. 46(29):2866-89

[13] Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016. Vol. 37(22):1720-2

[14] Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016. Vol. 118(4):620-36

[15] Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019. Vol. 124(2):315-27

[16] Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014. Vol. 114(12):1852-66

[17] Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011. Vol. 473(7347):317-25

[18] Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005. Vol. 352(16):1685-95

[19] Popa-Fotea NM, Ferdoschi CE, Micheu MM. Molecular and cellular mechanisms of inflammation in atherosclerosis. Front Cardiovasc Med. 2023. Vol. 10:1200341

[20] Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al..ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023. Vol. 44(38):3720-826.

[21] Biasucci LM, Liuzzo G, Angiolillo DJ, Sperti G, Maseri A. Inflammation and acute coronary syndromes. Herz. 2000. Vol. 25(2):108-12

[22] Ross R.Atherosclerosis--an inflammatory disease. N Engl J Med. 1999. Vol. 340(2):115-26

[23] Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, et al.. Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (stabilization of plaque using darapladib-thrombolysis in myocardial infarction 52) trial. J Am Heart Assoc. 2017. Vol. 6(10):e005637

[24] Pérez Fernández R, Kaski JC. Interleukin-10 and coronary disease. Rev Esp Cardiol. 2002. Vol. 55(7):738-50

[25] Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al.. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002. Vol. 106(1):24-30

[26] Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013. Vol. 368(21):2004-13

[27] Ridker PM, Lüscher TF.Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014. Vol. 35(27):1782-91

[28] Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006. Vol. 69(3):614-24

[29] Tanase DM, Valasciuc E, Anton IB, Gosav EM, Dima N, Cucu AI, et al.. Matrix metalloproteinases: pathophysiologic implications and potential therapeutic targets in cardiovascular disease. Biomolecules. 2025. Vol. 15(4):598

[30] Ain QU, Dewi TI, Kurniati NF. Plasma levels of Interleukin-6 and -18 significantly increase in patients with acute coronary syndrome. Oman Med J. 2023. Vol. 38(4):e532

[31] Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res. 2008. Vol. 58(2):88-111

[32] Ihim SA, Abubakar SD, Zian Z, Sasaki T, Saffarioun M, Maleknia S, et al.. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment. Front Immunol. 2022. Vol. 13:919973

[33] Yang Y, Li G, Zhang R. Correlation analysis of acute coronary syndrome with serum IL-18, MMP-9, hs-CRP, and plasma FIB. Biomed Res Int. 2022. Vol. 2022(1):5984184.

[34] Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, et al.. NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024. Vol. 9(1):53

[35] Brie DM, Mornoș C, Adam O, Tîrziu A, Popescu R, Brie AD. Inflammatory mechanisms in acute coronary syndromes: from pathophysiology to therapeutic targets. Cells. 2025. Vol. 15(1):72

[36] O’Brien LC, Mezzaroma E, Van Tassell BW, Marchetti C, Carbone S, Abbate A, et al.. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med. 2014. Vol. 20(1):221-9

[37] Jameel N, Dwivedi A, Khushtar M, Haider MF, Nematullah M, Rahman MA. Inflammation demystified: an in-depth comprehensive review. Biomed Res Ther. 2025. Vol. 12(10):7820-36

[38] Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial. J Am Coll Cardiol. 2020. Vol. 76(14):1660-70

[39] Kemp M, Donovan J, Higham H, Hooper J. Biochemical markers of myocardial injury. Br J Anaesth. 2004. Vol. 93(1):63-73

[40] Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ. 2005. Vol. 173(10):1191-202

[41] Zafar Gondal A, Foris LA, Zubair M, Richards JR. Serum myoglobinStatPearls. Treasure Island, FL: StatPearls Publishing. 2025.

[42] Patibandla S, Gupta K, Alsayouri K. Cardiac biomarkersStatPearls. Treasure Island, FL: StatPearls Publishing. 2025.

[43] White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol. 2011. Vol. 57(24):2406-8

[44] Januzzi JL Jr, Mahler SA, Christenson RH, Rymer J, Newby LK, Body R, et al.. Recommendations for institutions transitioning to high-sensitivity troponin testing: JACC scientific expert panel. J Am Coll Cardiol. 2019. Vol. 73(9):1059-77

[45] Sahu AK, Goel PK, Khanna R, Kumar S, Kapoor A, Tewari S, et al.. Neutrophil gelatinase-associated lipocalin as a marker for contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective observational analysis. Indian J Nephrol. 2022. Vol. 32(3):247-55

[46] Thielmann M, Sharma V, Al-Attar N, Bulluck H, Bisleri G, Bunge JJH, et al.. ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: perioperative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery. Eur Heart J. 2017. Vol. 38(31):2392-407

[47] Galassi A, Ciceri P, Bono V, Magagnoli L, Sala M, Artioli L, et al.. Growth differentiation factor 15 (GDF-15) levels associate with lower survival in chronic kidney disease patients with COVID-19. Biomedicines. 2022. Vol. 10(12):3251

[48] Gürgöze MT, van Vark LC, Baart SJ, Kardys I, Akkerhuis KM, Manintveld OC, et al.. Multimarker analysis of serially measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, creatinine, and prognosis in acute heart failure. Circ Heart Fail. 2023. Vol. 16(1):e009526

[49] Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al.. Fourth universal definition of myocardial infarction. Circulation. 2018. Vol. 138(20):e618-51

[50] Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin. 2001. Vol. 19(4):557-71

[51] Mueller C, Möckel M, Giannitsis E, Huber K, Mair J, Plebani M, et al.. Use of copeptin for rapid rule-out of acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2018. Vol. 7(6):570-6

[52] Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al.. Circulating microRNA-208b and MICRORNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010. Vol. 3(6):499-506

[53] Wang J, Han LN, Ai DS, Wang XY, Zhang WJ, Xu XR, et al.. Growth differentiation factor 15 predicts cardiovascular events in stable coronary artery disease. J Geriatr Cardiol. 2023. Vol. 20(7):527-37

[54] Gururajan P, Gurumurthy P, Nayar P, Srinivasa Nageswara Rao G, Babu S, Cherian KM. Heart fatty acid binding protein (H-FABP) as a diagnostic biomarker in patients with acute coronary syndrome. Heart Lung Circ. 2010. Vol. 19(11):660-4

[55] McCarthy CP, Januzzi JL Jr. Soluble St 2 in heart failure. Heart Failure Clinics. 2018. Vol. 14(1):41-8

[56] Chen J, Jiang L, Yu XH, Hu M, Zhang YK, Liu X, et al.. Endocan: a key player of cardiovascular disease. Front Cardiovasc Med. 2022. Vol. 8:798699

[57] Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al.. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012. Vol. 58(1):267-73

[58] Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-Arginine Paradox” and acts as a novel cardiovascular risk factor. J Nutr. 2004. Vol. 134 10 Suppl:2842S-7S

[59] Xiong X, Yuan L, Long X, An M, Huang S, Liu L. Cystatin C as a biomarker for identifying high-risk patients with acute coronary syndrome: an observational study. Clin Appl Thromb Hemost. 2025. Vol. 31:10760296251324201

[60] Knapp M, Gil-Mika M, Sawicki R, Lisowska A, Kaminski M, Sobkowicz B, et al.. Pentraxin 3 as a marker of development and severity of stable coronary artery disease. Adv Med Sci. 2024. Vol. 69(2):391-7

[61] Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010. Vol. 4(2):265-80

[62] Matsui M, Uemura S, Takeda Y, Samejima K, Matsumoto T, Hasegawa A, et al.. Placental growth factor as a predictor of cardiovascular events in patients with CKD from the NARA-CKD study. J Am Soc Nephrol. 2015. Vol. 26(11):2871-81

[63] Palladini G, Barassi A, Perlini S, Milani P, Foli A, Russo P, et al.. Mid-regional pro-adrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid. 2011. Vol. 18(4):216-21

[64] Di Febo R, Saeed Z, Serafini F, Brocco D, D’Ascanio F, Pizzi AD, et al.. Diagnostic and prognostic roles of endothelial-and platelet-derived extracellular vesicles in cardiovascular diseases. J Transl Med. 2025. Vol. 23(1):553

[65] Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A₂: role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. 2011. Vol. 2(1):27-38

[66] VanPatten S, Al-Abed Y. High Mobility Group Box-1 (HMGb1): current wisdom and advancement as a potential drug target. J Med Chem. 2018. Vol. 61(11):5093-107

[67] Li M, Duan L, Cai YL, Li HY, Hao BC, Chen JQ, et al.. Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease. Cardiovasc Diabetol. 2020. Vol. 19(1):120

[68] Riccardi M, Myhre PL, Zelniker TA, Metra M, Januzzi JL, Inciardi RM. Soluble ST 2 in heart failure: a clinical role beyond B-type natriuretic peptide. J Cardiovasc Dev Dis. 2023. Vol. 10(11):468

[69] Tian L, Chen K, Han Z. Correlation between galectin-3 and adverse outcomes in myocardial infarction patients: a meta-analysis. Cardiol Res Pract. 2020. Vol. 2020(1):7614327

[70] Ge Y, Huang M, Yao YM. The effect and regulatory mechanism of high mobility group Box-1 protein on immune cells in inflammatory diseases. Cells. 2021. Vol. 10(5):1044

[71] Mu D, Cheng J, Qiu L, Cheng X. Copeptin as a diagnostic and prognostic biomarker in cardiovascular diseases. Front Cardiovasc Med. 2022. Vol. 9:901990

[72] Pinchi E, Frati P, Aromatario M, Cipolloni L, Fabbri M, La Russa R, et al.. miR-1, miR-499 and miR-208 are sensitive markers to diagnose sudden death due to early acute myocardial infarction. J Cell Mol Med. 2019. Vol. 23(9):6005-16

[73] Vupputuri A, Sekhar S, Krishnan S, Venugopal K, Natarajan KU. Heart-type fatty acid-binding protein (H-FABP) as an early diagnostic biomarker in patients with acute chest pain. Indian Heart J. 2015. Vol. 67(6):538-42

[74] Kanyal S, Das A, Bashir AMD, Syed AH, Aujla S, Chaudhary J, et al.. N-terminal pro-B-type natriuretic peptide (NT-proBNP) as a biomarker in heart failure with preserved ejection fraction (HFpEF) versus heart failure with reduced ejection fraction (HFrEF): the way forward in the age of proteomics. Cureus. 2025. Vol. 17(10):e94162

[75] Buendgens L, Yagmur E, Ginsberg A, Weiskirchen R, Wirtz T, Jhaisha SA, et al.. Midregional proadrenomedullin (MRproADM) serum levels in critically Ill patients are associated with short-term and overall mortality during a two-year follow-up. Mediators Inflamm. 2020. Vol. 2020(1):7184803

[76] Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010. Vol. 6(2):82-90

[77] Li J, Wang H, Tian J, Chen B, Du F. Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome. Medicine (Baltimore). 2018. Vol. 97(28):e11517

[78] Wolosowicz M, Prokopiuk S, Kaminski TW. Matrix metalloproteinase-9 (MMP-9) as a therapeutic target: insights into molecular pathways and clinical applications. Pharmaceutics. 2025. Vol. 17(11):1425

[79] Kumric M, Borovac JA, Martinovic D, Ticinovic Kurir T, Bozic J. Circulating biomarkers reflecting destabilization mechanisms of coronary artery plaques: are we looking for the impossible? Biomolecules. 2021. Vol. 11(6):881

[80] Kilic ID, Caiazzo G, Fabris E, Serdoz R, Abou-Sherif S, Madden S, et al.. Near-infrared spectroscopy-intravascular ultrasound: scientific basis and clinical applications. Eur Heart J Cardiovasc Imaging. 2015. Vol. 16(12):1299-306

[81] Zimbardo G, Cialdella P, Di Fusco P, Donahue ME, D’Aquino UML, Paolucci L, et al.. Acute coronary syndromes and multivessel coronary artery disease. Eur Heart J Suppl. 2023. Vol. 25 Suppl C:C74-8

[82] Rao SV, O’Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al.. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025. Vol. 85(22):2135-237

[83] Aletras G, Bachlitzanaki M, Stratinaki M, Lamprogiannakis E, Petrakis I, Foukarakis E, et al.. Integrating novel biomarkers into clinical practice: a practical framework for diagnosis and management of cardiorenal syndrome. Life (Basel). 2025. Vol. 15(10):1540

[84] Netala VR, Hou T, Wang Y, Zhang Z, Teertam SK. Cardiovascular biomarkers: tools for precision diagnosis and prognosis. Int J Mol Sci. 2025. Vol. 26(7):3218

[85] Widera C, Pencina MJ, Meisner A, Kempf T, Bethmann K, Marquardt I, et al.. Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. Eur Heart J. 2012. Vol. 33(9):1095-104

[86] Sun C, Zhong L, Wu Y, Cao C, Guo D, Liu J, et al.. Incorporation of laboratory test biomarkers into dual antiplatelet therapy score improves prediction of ischemic and bleeding events in post-percutaneous coronary intervention patients. Front Cardiovasc Med. 2022. Vol. 9:834975

[87] Abhilash B, Ramesh Y, Penabaka V, Chandra YP. Novel biomarkers in early disease detection. GSC Biol Pharm Sci. 2025. Vol. 33(1):364-76

[88] Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al.. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006. Vol. 17(7):2034-47

[89] Wang J, Wei L, Yang X, Zhong J. Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. J Am Heart Assoc. 2019. Vol. 8(17):e012826

[90] Huang S, Yu LJ, Sun GF, Zhang ZX. Short-term predictive value of sST 2 in patients with STEMI following primary PCI: a prospective observational study. BMC Cardiovasc Disord. 2025. Vol. 25(1):21

[91] Li YQ, Zhang MF, Wen HY, Hu CL, Liu R, Wei HY, et al.. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics (Sao Paulo). 2013. Vol. 68(1):75-80

[92] Kost GJ, Kost LE, Suwanyangyuen A, Cheema SK, Curtis C, Sumner S, et al.. Emergency cardiac biomarkers and point-of-care testing: optimizing acute coronary syndrome care usingsmall-world networks in rural settings. Point Care. 2010. Vol. 9(2):53-64

[93] Westwood M, Ramaekers B, Grimm S, Worthy G, Fayter D, Armstrong N, et al.. High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation. Health Technol Assess. 2021. Vol. 25(33):1-276

[94] Latini R, Masson S. NT-proBNP: a guide to improve the management of patients with heart failure. EJIFCC. 2013. Vol. 24(3):78-84

[95] Wang Y, Aivalioti E, Stamatelopoulos K, Zervas G, Mortensen MB, Zeller M, et al.. Machine learning in cardiovascular risk assessment: towards a precision medicine approach. Eur J Clin Invest. 2025. Vol. 55 Suppl 1:e70017

[96] Varghese MS, Liu CL, Kazi DS. The price of progress: cost, access, and adoption of novel cardiovascular drugs in clinical practice. Curr Cardiol Rep. 2021. Vol. 23(11):163

[97] Wang L, Cong HL, Zhang JX, Li XM, Hu YC, Wang C, et al.. Prognostic performance of multiple biomarkers in patients with acute coronary syndrome without standard cardiovascular risk factors. Front Cardiovasc Med. 2022. Vol. 9:916085

[98] Ng S, Masarone S, Watson D, Barnes MR. The benefits and pitfalls of machine learning for biomarker discovery. Cell Tissue Res. 2023. Vol. 394(1):17-31

[99] Rodriguez-Lozano PF, Waheed A, Evangelou S, Kolossváry M, Shaikh K, Siddiqui S, et al.. CT derived fractional flow reserve: part 2 -critical appraisal of the literature. J Cardiovasc Comput Tomogr. 2025. Vol. 19(4):397-408

[100] Singh B, Karpov OA, Mayr M. Clinical proteomics in cardiovascular medicine: current capabilities, limitations, and future directions. Atherosclerosis. 2026. Vol. 413:120637